Prominent Harvard Chemist Arrested For Concealing Ties to China

The Department of Justice also released the names of two Chinese researchers who allegedly acted against US interests.

Written byAmy Schleunes
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Charles Lieber, chair of the department of chemistry and chemical biology at Harvard University, has been arrested and charged with one count of making a false statement to federal authorities, according to a Department of Justice press release published yesterday (January 28).

“Unbeknownst to Harvard University beginning in 2011, Lieber became a ‘Strategic Scientist’ at Wuhan University of Technology (WUT) in China and was a contractual participant in China’s Thousand Talents Plan from in or about 2012 to 2017,” the justice department statement says. At the same time, he also received funding from US federal agencies, including the National Institutes of Health (NIH) and Department of Defense, which require researchers to disclose if they receive aid from foreign governments or foreign entities. Lieber did: In connection with the Chinese programs, he received $50,000 USD per month, living expenses of up to 1,000,000 Chinese Yuan (approximately $158,000 USD at the time), ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • A former intern at The Scientist, Amy studied neurobiology at Cornell University and later earned her MFA in creative writing from the University of Iowa. She is a Los Angeles–based writer, editor, and communications strategist who collaborates on nonfiction books for Harper Collins and Houghton Mifflin Harcourt, and also teaches writing at Johns Hopkins University CTY. Her favorite projects involve sharing the insights of science and medicine.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies